Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

Last updated : May 6, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

Strategies to promote BYOD adoption by clinical study sites

Empowering patients through data: a collaborative vision of clinical data...

If Patients Want A Better Quality Of Life, Why Isn’t...

Strategies to overcome clinical trials complexities

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

5th Annual Clinical Trial Innovation Summit

JUNE 26, 2025 • Basel, CH

Clinical Trial Innovation Summit 2025 | June 26, 2025

The reckless value of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....